Short Interest in Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Drops By 32.5%

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) saw a large decline in short interest in January. As of January 15th, there was short interest totaling 3,991,736 shares, a decline of 32.5% from the December 31st total of 5,910,789 shares. Based on an average daily volume of 1,084,209 shares, the days-to-cover ratio is presently 3.7 days. Currently, 7.3% of the shares of the company are short sold. Currently, 7.3% of the shares of the company are short sold. Based on an average daily volume of 1,084,209 shares, the days-to-cover ratio is presently 3.7 days.

Institutional Trading of Zevra Therapeutics

A number of hedge funds have recently bought and sold shares of ZVRA. CWM LLC grew its stake in Zevra Therapeutics by 399.5% in the 3rd quarter. CWM LLC now owns 2,872 shares of the company’s stock worth $27,000 after acquiring an additional 2,297 shares during the period. Ameritas Investment Partners Inc. lifted its holdings in shares of Zevra Therapeutics by 30.0% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 5,541 shares of the company’s stock worth $49,000 after acquiring an additional 1,280 shares during the period. Russell Investments Group Ltd. raised its stake in Zevra Therapeutics by 235.7% during the third quarter. Russell Investments Group Ltd. now owns 6,374 shares of the company’s stock worth $61,000 after purchasing an additional 4,475 shares during the period. Tower Research Capital LLC TRC boosted its holdings in shares of Zevra Therapeutics by 617.5% in the 2nd quarter. Tower Research Capital LLC TRC now owns 9,937 shares of the company’s stock valued at $88,000 after purchasing an additional 8,552 shares during the last quarter. Finally, Creative Planning purchased a new stake in shares of Zevra Therapeutics during the 2nd quarter valued at $92,000. Institutional investors and hedge funds own 35.03% of the company’s stock.

Zevra Therapeutics Stock Performance

NASDAQ:ZVRA opened at $9.00 on Friday. The company has a current ratio of 8.62, a quick ratio of 8.57 and a debt-to-equity ratio of 0.46. The company has a market capitalization of $506.70 million, a P/E ratio of 19.15 and a beta of 1.08. The firm has a 50-day moving average price of $8.64 and a two-hundred day moving average price of $9.47. Zevra Therapeutics has a twelve month low of $6.19 and a twelve month high of $13.16.

Zevra Therapeutics (NASDAQ:ZVRA) last released its quarterly earnings results on Wednesday, November 5th. The company reported ($0.01) EPS for the quarter, beating the consensus estimate of ($0.04) by $0.03. Zevra Therapeutics had a net margin of 41.93% and a negative return on equity of 51.40%. The business had revenue of $26.06 million for the quarter, compared to analyst estimates of $26.64 million. As a group, research analysts expect that Zevra Therapeutics will post -1.95 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms have recently commented on ZVRA. Canaccord Genuity Group reduced their price target on Zevra Therapeutics from $25.00 to $24.00 and set a “buy” rating for the company in a report on Thursday, November 6th. Weiss Ratings reiterated a “sell (d+)” rating on shares of Zevra Therapeutics in a research report on Friday, January 9th. Wall Street Zen upgraded shares of Zevra Therapeutics from a “hold” rating to a “buy” rating in a research report on Saturday, November 8th. Cantor Fitzgerald cut their price target on shares of Zevra Therapeutics from $29.00 to $24.00 and set an “overweight” rating for the company in a report on Thursday, November 6th. Finally, HC Wainwright set a $26.00 price objective on shares of Zevra Therapeutics in a research note on Tuesday, December 30th. Six equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Zevra Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $22.80.

Zevra Therapeutics Company Profile

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 1/2 clinical trial for the treatment of vascular Ehlers Danlos syndrome.